无抑制物重型A型血友病患者接受艾美赛珠单抗预防治疗的 management:AICE推荐意见,聚焦急诊,与SIBioC、SIMEU、SIMEUP、SIPMeL和SISET协作制定
艾美赛珠单抗是一种FVIII模拟双特异性单克隆抗体,先前获批用于伴抑制物的A型血友病预防治疗,近期在多个国家获批用于无抑制物的重型A型血友病(PWSHA)患者。该药引入后需在血友病治疗中心(HTC)建立特定路径,尤其涉及实验室检测、突破性出血和侵入性操作/手术的治疗,在非专科人员管理患者时更为关键。目前关于无抑制物PWSHA患者使用艾美赛珠单抗的文献数据和临床经验有限。意大利血友病中心协会(AICE)发布指南,聚焦急诊管理,并与5个止血、实验室和急诊科学学会共同修订,提供关于使用FVIII浓缩物治疗出血或为侵入性操作/手术提供止血覆盖以及实验室监测的一般推荐,强调急诊科管理需HTC专科医师直接参与或正式监督。
要点
- AICE指南针对无抑制物重型A型血友病接受艾美赛珠单抗预防治疗的患者,提供急诊管理路径,强调需HTC专科医师直接参与或正式监督。
- 指南提供关于使用FVIII浓缩物治疗出血或为侵入性操作/手术提供止血覆盖的一般推荐。
- 指南提供关于实验室监测的一般推荐,适用于无抑制物PWSHA接受艾美赛珠单抗预防治疗的患者。
- 目前关于无抑制物PWSHA患者使用艾美赛珠单抗的文献数据和临床经验有限。
- 该指南由AICE专家小组起草,经在线咨询批准,并由包括5个学会成员的多学科工作组修订,最终由各学会理事会批准。
适用人群与场景
- 无抑制物的重型A型血友病(PWSHA)患者,正在接受艾美赛珠单抗预防治疗。
- 急诊科场景,尤其涉及非专科专业人员管理时。
处置流程与药物剂量
- 急诊科管理需HTC专科医师直接参与或正式监督。
研究设计与关键结果
- AICE专家小组起草指南,经在线咨询批准,并由包括5个止血、实验室和急诊科学学会成员的多学科工作组修订,最终由各学会理事会批准。
- 指南提供关于使用FVIII浓缩物治疗出血或为侵入性操作/手术提供止血覆盖以及实验室监测的一般推荐。
- 指南聚焦急诊科管理的特定问题,强调需HTC专科医师直接参与或正式监督。
证据类型、等级与局限
- 证据类型:指南(AICE推荐意见),经多学科工作组修订并经各学会理事会批准。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该指南为不同医疗机构提供了参考路径,尤其针对该背景下具有挑战性的急诊管理。
- 作者认为,在急诊科管理中,需HTC专科医师直接参与或正式监督。
- 作者认为,需在血友病治疗中心(HTC)建立特定路径,尤其涉及实验室检测、突破性出血和侵入性操作/手术的治疗。
指南或共识出处
- 指南名称:Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET
- 发布机构:意大利血友病中心协会(AICE),与SIBioC、SIMEU、SIMEUP、SIPMeL和SISET协作
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The factor VIII (FVIII)-mimetic bispecific monoclonal antibody, emicizumab, previously approved for prophylaxis in haemophilia A with inhibitors, has been recently licensed in several countries also in patients with severe haemophilia A (PWSHA) without inhibitors. The introduction of this innovative agent requires the development of specific pathways at Haemophilia Treatment Centres (HTC), particularly regarding laboratory testing and treatment of breakthrough bleeds and invasive procedures/surgeries, even more critical when patients are managed by non-specialist professionals. Limited literature data and clinical experience in PWSHA without inhibitors on emicizumab are currently available.
AIM: To promote awareness and overcome these challenges, the Italian Association of Haemophilia Centres (AICE) issued a guidance on the management of PWSHA without inhibitors on emicizumab prophylaxis, focused on emergency and shared with other National Scientific Societies in the field.
METHODS: The document, drafted by an AICE expert panel and approved through online consultation, was further revised by a multidisciplinary working group, including members of 5 haemostasis, laboratory and emergency scientific societies. The final version was approved by the Council of each society.
RESULTS: General recommendations about use of FVIII concentrates for the treatment of bleeding or haemostatic coverage of invasive procedures/surgeries and laboratory monitoring in PWSHA without inhibitors on emicizumab are provided. Specific issues of the management in the emergency room are focused, highlighting the need for direct involvement or formalized supervision by specialist HTC physicians.
CONCLUSIONS: This guidance provides a reference pathway to be implemented in the different healthcare organizations, especially for the challenging emergency management in this setting.
参考来源
- Coppola A, Castaman G, Santoro RC, et al. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia. 2020. PMID: 33094880. doi:10.1111/hae.14172
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。